HER2 Assessment by Immunohistochemical Analysis and Fluorescence In Situ Hybridization

This publication has 17 references indexed in Scilit:

• Quantitative Evaluation of HER-2/neuStatus in Breast Cancer by Fluorescence In Situ Hybridization and by Immunohistochemistry With Image Analysis
  American Journal of Clinical Pathology, 2001
• Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message
  Journal of Clinical Oncology, 2001
• New adjuvant strategies for breast cancer: Meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin)
  Seminars in Oncology, 2001
• Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials
  Seminars in Oncology, 2001
• HER-2/neu Gene Amplification Compared With HER-2/neu Protein Overexpression and Interobserver Reproducibility in Invasive Breast Carcinoma
  American Journal of Clinical Pathology, 2000
• ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
  The EMBO Journal, 1997
• ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.
  Proceedings of the National Academy of Sciences, 1992
• The subcellular localization of the neu protein in human normal and neoplastic cells
  International Journal of Cancer, 1989
• Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
  Science, 1989
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987